Epoetin alfa dizziness

CRF patients - Epoetin alfa is generally well tolerated. The following adverse reactions are frequent (greater than 3%) sequelae of CRF and are not necessarily due to epoetin alfa therapy hypertension, headache, arthralgia, nausea, edema, fatigue, diarrhea, vomiting, chest pain, asthenia, dizziness, skin reaction, and clotted vascular access. 

Epoetin Alfa [Erythropoietin/ EPO] (Epogen/ Procrit) [Recombinant Human Erythropoietin] WARNING Use lowest dose possible may be associated w/1 CV, thromboembolic events /or mortality D/C if Hgb >12 g/dL Uses CRF associated anemia zidovudine Rx in HIV-infected pts, CA chemo -1- transfusions associated w/ surgery Action Induces ery-thropoiesis Dose Adul Peds. 50-150 Units/kg IV/SQ 3x/wk adjust dose q4-6wk PRN Surgery 300 Units/kg/d x 10 d before to 4 d after -I dose if Hct 36% or Hgb, T > 12 g/dL or Hgb t >1 g/dL in 2-wk pmod hold dose if Hgb >12 g/dL Caution [C, +] Contra Uncontrolled HTN Disp Inj SE HTN, HA, fatigue, fever, tach, NA Interactions None noted EMS Monitor ECG for hypokalemia (peaked T waves) t risk of CV thrombotic events OD May cause HA, dizziness, SOB and polycythemia symptomatic and supportive... 

The most frequently reported adverse events are headache, polycythemia, tiredness, common cold, diarrhea, nausea, stomach pains, chest pressure sensation, back pain, leg pain, and dizziness, as confirmed in a phase I open bioequivalence parallel group study of two recombinant human epoetin alfa products the pattern of the adverse events revealed no relevant differences between the erythropoietin derivatives [95 ]. Patients who were randomized to early intervention with immediate epoetin alfa (n = 68) or to standard intervention with epoetin alfa (n = 68), and a further 50 who were not randomized, pain, injection-site pain, bone pain, and deep vein thrombosis were observed [96 ]. 

---

See also in sourсe #XX -- [ ]

---